Cyclin D1 splice site variant triggers chromosomal aberrations in healthy humans

Leukemia

Volumn 28, Issue 3, 2014, Pages 721-722

  Hemminki, K ^a,b   Musak, L ^c   Vymetalkova, V ^d,e   Smerhovsky, Z ^e   Halasova, E ^f   Osina, O ^c   Letkova, L ^f   Forsti A ^a,b   Vodickova, L ^d,e   Buchancova, J ^f   Vodicka, P ^d,e  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b LUND UNIVERSITY   (Sweden)

^c Martinska Fakultna Nemocnica   (Slovakia)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

^f University Hospital in Martin   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; DOUBLE STRANDED DNA;

ADULT; AGED; CANCER RISK; CELL TYPE; CHROMOSOME ABERRATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LETTER; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MITOSIS; MULTIPLE MYELOMA; PRIORITY JOURNAL; QUALITY CONTROL; ULTRAVIOLET RADIATION; YOUNG ADULT;

CHROMOSOME ABERRATIONS; DNA DAMAGE; HUMANS; REFERENCE VALUES; RNA SPLICING;

EID: 84895826663     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.353     Document Type: Letter

References (13)

1. Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer 2007; 7: 233-245.
2. Albertini RJ, Anderson D, Douglas GR, Hagmar L, Hemminki K, Merlo F et al. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. International Programme on Chemical Safety. Mutat Res 2000; 463: 111-172.
3. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
4. Bonassi S, Norppa H, Ceppi M, Stromberg U, Vermeulen R, Znaor A et al. Chromosomal aberration frequency in lymphocytes predicts the risk of cancer: Results from a pooled cohort study of 22 358 subjects in 11 countries. Carcinogenesis 2008; 29: 1178-1183.
5. Vodicka P, Polivkova Z, Sytarova S, Demova H, Kucerova M, Vodickova L et al. Chromosomal damage in peripheral blood lymphocytes of newly diagnosed cancer patients and healthy controls. Carcinogenesis 2010; 31: 1238-1241.
6. Weinhold N, Johnson DC, Chubb D, Chen B, Fö rsti A, Hosking FJ et al. The CCND1 G870A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nature Genet 2013; 45: 522-525.
7. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES. Cyclin D1: Polymorphism, aberrant splicing and cancer risk. Oncogene 2006; 25: 1620-1628.
8. Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011; 11: 558-572.
9. Musak L, Smerhovsky Z, Halasova E, Osina O, Letkova L, Vodickova L et al. Chromosomal damage among medical staff occupationally exposed to volatile anesthetics, antineoplastic drugs, and formaldehyde. Scand J Work Environ Health 2013; 39: 618-630.
10. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer 2012; 12: 335-348.
11. Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu Rev Immunol 2011; 29: 319-350.
12. Jirawatnotai S, Hu Y, Michowski W, Elias JE, Becks L, Bienvenu F et al. A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers. Nature 2011; 474: 230-234.
13. Li Z, Jiao X, Wang C, Shirley LA, Elsaleh H, Dahl O et al. Alternative cyclin D1 splice forms differentially regulate the DNA damage response. Cancer Res 2010; 70: 8802-8811..